Cargando…

Comparative evaluation of staging algorithms proven N2 non-small cell lung cancer treated by lung resection after neoadjuvant therapy

BACKGROUND: In this study, we aimed to compare the performances of clinical methods, minimally invasive methods, mediastinoscopy, and re-mediastinoscopy used in the restaging of patients receiving neoadjuvant therapy for pathologically proven N2. Our secondary objective was to determine the most opt...

Descripción completa

Detalles Bibliográficos
Autores principales: İşgörücü, Özgür, Çıtak, Necati, Açıkmeşe, Barış, Akalın Fener, Neslihan, Büyükkale, Songül, Sayar, Adnan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bayçınar Medical Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580280/
https://www.ncbi.nlm.nih.gov/pubmed/36303707
http://dx.doi.org/10.5606/tgkdc.dergisi.2022.21347
_version_ 1784812358065979392
author İşgörücü, Özgür
Çıtak, Necati
Açıkmeşe, Barış
Akalın Fener, Neslihan
Büyükkale, Songül
Sayar, Adnan
author_facet İşgörücü, Özgür
Çıtak, Necati
Açıkmeşe, Barış
Akalın Fener, Neslihan
Büyükkale, Songül
Sayar, Adnan
author_sort İşgörücü, Özgür
collection PubMed
description BACKGROUND: In this study, we aimed to compare the performances of clinical methods, minimally invasive methods, mediastinoscopy, and re-mediastinoscopy used in the restaging of patients receiving neoadjuvant therapy for pathologically proven N2. Our secondary objective was to determine the most optimal algorithm for initial staging and restaging after neoadjuvant therapy. METHODS: Between April 2003 and August 2017, a total of 105 patients (99 males, 6 females; mean age: 54.5±8.2 years; range, 27 to 73 years) who were diagnosed with pathologically proven Stage 3A-B N2 non-small cell lung cancer and received neoadjuvant therapy and subsequently lung resection were retrospectively analyzed. Staging algorithm groups (Group 1=first mediastinoscopy-second clinic, Group 2=first mediastinoscopy-second minimally invasive, Group 3=first mediastinoscopy-second re-mediastinoscopy, and Group 4=first minimally invasive-second mediastinoscopy) were created and compared. RESULTS: In the first stage, N2 diagnosis was made in 90 patients by mediastinoscopy and in 15 patients by minimally invasive method. In the second stage, 44 patients were restaged by the clinical method, 23 by the minimally invasive method, 23 by re-mediastinoscopy, and 15 by mediastinoscopy. The false negativity rates of Groups 1, 2, 3, and 4 were 27.2%, 26.1%, 21.8%, and 13.3%, respectively. The most reliable staging algorithm was found to be the minimally invasive method in the first step and mediastinoscopy in the second step. The mean overall five-year survival rate was 46.3±4.4%, and downstaging in lymph node involvement was found to have a favorable effect on survival (54.3% vs. 21.8%, respectively; p=0.003). CONCLUSION: The staging method to be chosen before and after neoadjuvant therapy is critical in the treatment of Stage 3A-B N2 non-small cell lung cancer. In re-mediastinoscopy, the rate of false negativity increases due to technical difficulties and insufficient sampling. As the most optimal staging algorithm, the minimally invasive method is recommended in the first step and mediastinoscopy in the second step.
format Online
Article
Text
id pubmed-9580280
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Bayçınar Medical Publishing
record_format MEDLINE/PubMed
spelling pubmed-95802802022-10-26 Comparative evaluation of staging algorithms proven N2 non-small cell lung cancer treated by lung resection after neoadjuvant therapy İşgörücü, Özgür Çıtak, Necati Açıkmeşe, Barış Akalın Fener, Neslihan Büyükkale, Songül Sayar, Adnan Turk Gogus Kalp Damar Cerrahisi Derg Original Article BACKGROUND: In this study, we aimed to compare the performances of clinical methods, minimally invasive methods, mediastinoscopy, and re-mediastinoscopy used in the restaging of patients receiving neoadjuvant therapy for pathologically proven N2. Our secondary objective was to determine the most optimal algorithm for initial staging and restaging after neoadjuvant therapy. METHODS: Between April 2003 and August 2017, a total of 105 patients (99 males, 6 females; mean age: 54.5±8.2 years; range, 27 to 73 years) who were diagnosed with pathologically proven Stage 3A-B N2 non-small cell lung cancer and received neoadjuvant therapy and subsequently lung resection were retrospectively analyzed. Staging algorithm groups (Group 1=first mediastinoscopy-second clinic, Group 2=first mediastinoscopy-second minimally invasive, Group 3=first mediastinoscopy-second re-mediastinoscopy, and Group 4=first minimally invasive-second mediastinoscopy) were created and compared. RESULTS: In the first stage, N2 diagnosis was made in 90 patients by mediastinoscopy and in 15 patients by minimally invasive method. In the second stage, 44 patients were restaged by the clinical method, 23 by the minimally invasive method, 23 by re-mediastinoscopy, and 15 by mediastinoscopy. The false negativity rates of Groups 1, 2, 3, and 4 were 27.2%, 26.1%, 21.8%, and 13.3%, respectively. The most reliable staging algorithm was found to be the minimally invasive method in the first step and mediastinoscopy in the second step. The mean overall five-year survival rate was 46.3±4.4%, and downstaging in lymph node involvement was found to have a favorable effect on survival (54.3% vs. 21.8%, respectively; p=0.003). CONCLUSION: The staging method to be chosen before and after neoadjuvant therapy is critical in the treatment of Stage 3A-B N2 non-small cell lung cancer. In re-mediastinoscopy, the rate of false negativity increases due to technical difficulties and insufficient sampling. As the most optimal staging algorithm, the minimally invasive method is recommended in the first step and mediastinoscopy in the second step. Bayçınar Medical Publishing 2022-07-29 /pmc/articles/PMC9580280/ /pubmed/36303707 http://dx.doi.org/10.5606/tgkdc.dergisi.2022.21347 Text en Copyright © 2022, Turkish Society of Cardiovascular Surgery https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Article
İşgörücü, Özgür
Çıtak, Necati
Açıkmeşe, Barış
Akalın Fener, Neslihan
Büyükkale, Songül
Sayar, Adnan
Comparative evaluation of staging algorithms proven N2 non-small cell lung cancer treated by lung resection after neoadjuvant therapy
title Comparative evaluation of staging algorithms proven N2 non-small cell lung cancer treated by lung resection after neoadjuvant therapy
title_full Comparative evaluation of staging algorithms proven N2 non-small cell lung cancer treated by lung resection after neoadjuvant therapy
title_fullStr Comparative evaluation of staging algorithms proven N2 non-small cell lung cancer treated by lung resection after neoadjuvant therapy
title_full_unstemmed Comparative evaluation of staging algorithms proven N2 non-small cell lung cancer treated by lung resection after neoadjuvant therapy
title_short Comparative evaluation of staging algorithms proven N2 non-small cell lung cancer treated by lung resection after neoadjuvant therapy
title_sort comparative evaluation of staging algorithms proven n2 non-small cell lung cancer treated by lung resection after neoadjuvant therapy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580280/
https://www.ncbi.nlm.nih.gov/pubmed/36303707
http://dx.doi.org/10.5606/tgkdc.dergisi.2022.21347
work_keys_str_mv AT isgorucuozgur comparativeevaluationofstagingalgorithmsprovenn2nonsmallcelllungcancertreatedbylungresectionafterneoadjuvanttherapy
AT cıtaknecati comparativeevaluationofstagingalgorithmsprovenn2nonsmallcelllungcancertreatedbylungresectionafterneoadjuvanttherapy
AT acıkmesebarıs comparativeevaluationofstagingalgorithmsprovenn2nonsmallcelllungcancertreatedbylungresectionafterneoadjuvanttherapy
AT akalınfenerneslihan comparativeevaluationofstagingalgorithmsprovenn2nonsmallcelllungcancertreatedbylungresectionafterneoadjuvanttherapy
AT buyukkalesongul comparativeevaluationofstagingalgorithmsprovenn2nonsmallcelllungcancertreatedbylungresectionafterneoadjuvanttherapy
AT sayaradnan comparativeevaluationofstagingalgorithmsprovenn2nonsmallcelllungcancertreatedbylungresectionafterneoadjuvanttherapy